Related by context. Frequent words. (Click for all words.) 67 Berkeley HeartLab 63 BioMarin Genzyme LLC 61 -leukemias 60 Preliminary Third Quarter 60 XTENT 58 Overall NewMarket 58 Files Shelf Registration Statement 58 Excluding goodwill impairment 58 Normalized EBITDA 58 Ore Pharmaceuticals 58 f h 58 Celera Corporation 57 Sees Q3 57 AmeriPath 57 HLTH Corporation 57 Including discontinued operations 57 SangStat 57 -Eurocan 57 Esoterix 57 pershare 57 Condensed Consolidated Income 57 FQ = fiscal 57 USD #.#bln [001] 57 Idera Pharmaceuticals 56 Hanger Orthopedic 56 Universal Shelf Registration 56 pro forma adjusted EBITDA 56 Biosite Incorporated 56 Non GAAP adjusted EBITDA 56 Pharmion Corporation 56 NASDAQ LGND 56 ONEOK Partners segment 56 NV Organon 56 ACLARA 56 Hold Third Quarter 56 Harland Acquisition 56 Sees Q4 56 Q3 Loss Narrows 56 Merger Related 56 strategy GlobalData summarization 56 eResearchTechnology 56 Goodwill Impairment 55 = Net [039] 55 CFO Exercises Options 55 Sees FY# EPS 55 Pro forma EBITDA 55 Q2 Loss Widens 55 Vicuron Pharmaceuticals 55 Noninterest expense decreased 55 EBIT amounted 55 EntreMed Inc. 55 totaled MEUR 55 Sunesis Pharmaceuticals 55 FCF = 55 Biotest AG 55 Enzo Biochem 55 Intangibles amortization 55 Adjusted Diluted EPS 55 Q2 FY# [001] 55 Excluding nonrecurring items 55 CooperSurgical 55 Sees Q2 55 Raises FY# 55 normalized FFO 55 Syrrx 55 4Q FY# 54 Sees FY 54 Thermo Fisher Scientific TMO 54 b Excludes 54 excluding divestments 54 * Potentially libelous 54 IR BioSciences Holdings 54 debt extinguishments 54 Pretax Income 54 Molecular Devices Corporation 54 Petrosearch Energy 54 TargeGen 54 ofapproximately 54 OncoGenex Technologies 54 - Operating [004] 54 adjusted EBITDAR 54 Files Annual Report 54 Takeda Kyowa Hakko Kirin 54 3Q FY# 54 Preliminary Fourth Quarter 54 Unaudited Condensed Consolidated 54 EPIX Pharmaceuticals 54 ESP Pharma 53 - Operating [030] 53 Altus Pharmaceuticals 53 Inc. FY# Q3 53 Cyclacel Pharmaceuticals 53 Energy LLC DPLE 53 Pharsight Corporation 53 - Non GAAP [028] 53 = Net [006] 53 Nellix 53 Abraxis Bioscience 53 Stock Compensation Expense 53 ended December# 53 Trubion Pharmaceuticals